FindTrial
Sign In

Resveratrol and copper for the treatment of COVID-19 pnuemonia.

Routine use of over-the-counter Nutraceuticals, Resveretrol-Copper with standard treatment in Hospitalized Patients With Pneumonia/ Acute Respiratory Distress Syndrome Due To SARS-CoV-2 (Covid-19)- Retrospective Analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2020/06/026256
Enrollment
230
Registered
2020-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

TopiwalaNational Medical College and BYL Nair charitable Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male and non-pregnant female patients 1.Have positive reverse-transcriptaseâ??polymerase polymerase chain-reaction (RT-PCR) in a diagnostic specimen 2.Have pneumonia confirmed by chest imaging 3.oxygen saturation (Sao2) of 94% or less while they were breathing ambient air 4.have either normal levels of haematological, liver and renal functions, and electrolytes OR no worse than Grade 3 (CTCAE Version 5.0) abnormalities in any of these parameters

Exclusion criteria

Exclusion criteria: Asymptomatic or only mildly symptomatic

Design outcomes

Primary

MeasureTime frame
To retrospectively access the clinical outcomes in the patients receiving R- Cu along with standard treatment versus those who received standard treatment.Timepoint: 10 Days—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactRosemarie Desouza

T.N.M.C and B.Y.L.Nair Hospital

drrosemariedesouza@gmail.com9820056230

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026